Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Retreatment in Relapsed Multiple Myeloma
NCT03841565Phase 2Withdrawn
- Sponsor
- Academic and Community Cancer Research United
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Academic and Community Cancer Research United. Planned start Aug 2020; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03841565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841565.